黄惠涛;郝洁;张瑞;

• 1:郑州大学第一附属医院药学部

摘要(Abstract)：

血小板减少症是卡铂的剂量限制性毒性。根据肾小球滤过率(GFR)的变量改变影响游离卡铂曲线下面积(AUC)与所给剂量的线性关系,提出了卡铂按AUC给药的计算方法。目前临床上使用Calvert公式计算卡铂剂量,用Cockcroft-Gault公式计算出的肌酐清除率(Cr Cl)来代替GFR。但是Cockcroft-Gault公式在临床应用中也存在一些局限性。对卡铂的给药剂量计算策略进行综述,找到最佳剂量的计算方法,以供卡铂在临床合理用药和个体化治疗中参考。

关键词(KeyWords)： 卡铂;剂量;Calvert公式;Cockcroft-Gault公式;肾小球滤过率;曲线下面积;肌酐清除率

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划精准医学研究重点专项项目（2017YFC0909900）

作者(Author): 黄惠涛;郝洁;张瑞;

Email:

DOI:

参考文献(References)：

• [1]刘景辉.卡铂化疗致过敏性休克1例临床分析及护理管理[J].临床合理用药, 2018, 11(12A):22, 25.
• [2] Calvert A H, Newell D R, Gumbrell L A, et al.Carboplatin dosage:prospective evaluation of a simple formula based on renal function[J]. Clin Oncol, 1989,7(11):1748-1756.
• [3]李艳,宋晓坤,王怀冲. 1例肺大细胞神经内分泌癌肌酐异常患者使用卡铂剂量探讨[J].肿瘤防治研究,2019, 46(3):285-286.
• [4]吴宁.不同方法检测肌酐清除率的对比研究[J].中国医药科学, 2012, 2(2):132-133.
• [5]曾凤伟,程木华.肾小球滤过率的测定方法及进展[J].新医学, 2011, 42(2):123-126.
• [6] Janowitz, T, Williams E H, Marshall A, et al. New model for estimating glomerular filtration rate in patients with cancer[J]. J Clin Oncol, 2017, 35(24):2798-2805.
• [7] McLean L, Whittle J R, Graham J, et al. Carboplatin dosing in the era of IDMS-creatinine; the Cockroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care[J]. Gynecol Oncol, 2020, 157(3):793-798.
• [8] Herrington J D, Tran H T, Riggs M W. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia[J]. Cancer Chemother Pharmacol,2006, 57(2):241-247.
• [9] WHO. Obesity and overweight, www.who.int/mediacentre/factsheets/fs311/en/(2015, accessed 10 October 2017).
• [10] Sparreboom A, Wolff A C, Mathijssen R H J, et al.Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese[J]. J Clin Oncol, 2007,25(30):4707-4713.
• [11] Ekhart C, Rodenhuis S, Schellens J H M, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?[J]. Cancer Chemother Pharmacol, 2009, 64(1):115-122.
• [12] Cuesta C G, Jornet J E P, Blesa J M G, et al. Toxicity and effectiveness of carboplatin in obese or overweight patients[J]. J Oncol Pharm Pract, 2019, 25(6):1328-1335.
• [13] Cuesta-Grueso C, JoséA B, Cajaraville-Ordo?ana G, et al. Variability of carboplatin dose calculation methods in Spain[J]. J Oncol Pharm Pract, 2019, 25(7):1551-1557.
• [14]周陶然.采用实际体重或理想体重代入Cockroft-Gault公式计算肌酐清除率准确性的比较[J].药学服务与研究, 2017, 17(6):410, 418.
• [15] Morrow A, Garland C, Yang F, et al. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 m L/min:To cap or not to cap? A retrospective analysis and review[J]. J Oncol Pharm Pract, 2019, 25(7):1651-1657.
• [16] Griggs J J, Mangu P B, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer:American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2012, 30(13):1553-1561.
• [17] Oliver R T D, Mead G M, Rustin G J S, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma:mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study(ISRCTN27163214)[J]. J Clin Oncol, 2011, 29(8):957-962.
• [18]杜春双,焦建杰,包乐纹.卡铂按不同AUC给药对晚期卵巢上皮癌患者药动学参数的影响[J].中国药房,2013, 24(28):2637-2641.
• [19] Oguri T, Shimokata T, Ito I, et al. Extension of the Calvert formula to patients with severe renal insufficiency[J].Cancer Chemother Pharmacol, 2015, 76(1):53-59.
• [20] Shimokata T, Ando Y, Yasuda Y, et al. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer[J]. Cancer Sci, 2010, 101(12):2601-2605.
• [21] Würthwein G, Krefeld B, Gerss J, et al. Carboplatin dosing in children:calculation by different formulae[J].Onkologie, 2011, 34(1-2):16-22.